Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring EGFR mutation
{{output}}
Background: Adjuvant therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is effective and safe for patients with completely resected non-small cell lung cancer (NSCLC) with EGFR mutations, but cer... ...
